Cardiovascular News’ top 10 stories of July 2023


Hitting the headlines in July were new European guidelines on the treatment of arterial hypertension, several firsts in the field of transcatheter aortic valve implantation (TAVI), and an end to restrictions imposed on the use of paclitaxel-coated devices in peripheral arterial disease.

  1. New arterial hypertension guidelines update recommendations on the use of renal denervation
    New and expanded guidelines from the European Society of Hypertension (ESH) concerning the management of arterial hypertension state that renal denervation can be proposed as an adjunctive therapy in select patients with resistant hypertension.
  2. Keeping stroke at bay for patients undergoing TAVI
    Stroke—particularly disabling stroke—is among the major potential complications of a transcatheter aortic valve implantation (TAVI) procedure. In this advertorial, the second in a two-part series sponsored by Boston Scientific, interventional cardiologists Vlasis Ninios (Heart Center Thessaloniki, Kalamaria, Greece) and Ole De Backer (Rigshospitalet, Copenhagen, Denmark) reflect on the impact of stroke on the delivery of TAVI and offer their views on the key steps to limit its occurrence in their daily practice.
  3. Onecrea Medical announces successful first-in-human implants of Crea aortic valve
    Onecrea Medical has announced the success of the first-in-human implants of its transcatheter aortic valve implantation (TAVI) system for the treatment of aortic stenosis. The procedures were performed by a team under the supervision of Carlos Calderas (Policlinica Metropolitana, Caracas, Venezuela).
  4. Latest-generation DCBs “change thinking” on treatment of coronary artery disease
    Interventional cardiologists need to have a range of approaches and devices in their toolbox to treat the increasingly complex patient population entering the cath lab. Key among them, Victor Jimenez (Vigo, Spain) tells Cardiovascular News, are drug-coated balloons (DCBs), which can be used in a range of clinical scenarios in a DCB-only percutaneous coronary intervention (PCI) approach, or alongside drug-eluting stents (DESs) as part of a hybrid PCI strategy.
  5. ALL-RISE study of CathWorks FFRangio system enrols first patient
    CathWorks has announced that the first patient has been enrolled in the Advancing cath lab results with FFRangio coronary physiology assessment—ALL-RISE—study.
  6. Streamlined TAVI pathway paves the way for same-day discharge “record”
    Physicians at the James Cook University Hospital (Middlesbrough, UK) have performed ten transcatheter aortic valve implantation (TAVI) procedures in one day with seven patients returning home the same day and two the next morning. According to the centre, it is thought that the number of same day discharges is a first in the world for TAVI.
  7. Gut bacteria linked to coronary atherosclerotic plaques
    In a major Swedish study, researchers have discovered a link between the levels of certain bacteria living in the gut and coronary atherosclerotic plaques. The study was led by researchers at Uppsala and Lund University and the findings have been published in Circulation.
  8. Randomised trial “highly needed” to shed light on effectiveness of TAVI in bicuspid aortic stenosis patients
    A dedicated, prospective randomised controlled trial (RCT) investigating the safety, efficacy and limitations of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) in different types of bicuspid aortic stenosis is “highly needed”, according to researchers writing in JACC: Cardiovascular Interventions.
  9. Ian Meredith joins board of directors at Avertix Medical
    Avertix Medical—formerly known as Angel Medical Systems—has announced that Ian Meredith has agreed to join the company’s board of directors.
  10. Long-awaited US FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
    In a letter to healthcare providers dated 11 July 2023, the US Food and Drug Administration (FDA) communicates that the risk of mortality associated with paclitaxel-coated devices to treat peripheral arterial disease (PAD) is no longer supported based on the totality of the available data and analyses.



Please enter your comment!
Please enter your name here